

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE 2026 DISTRIBUTION AGREEMENTS

CONTINUING CONNECTED TRANSACTIONS

On April 8, 2026 (after trading hours), the Company (for itself and on behalf of its subsidiaries) and MicroPort® (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group) entered into the 2026 International Distribution Framework Agreement I and the 2026 International Distribution Framework Agreement II.

LISTING RULES IMPLICATIONS

As at the date of this announcement, MicroPort®, through its wholly-owned subsidiaries Shanghai MicroPort Limited and MicroPort International Corp. Limited, was indirectly interested in approximately 44.45% of the total issued share capital of the Company. Therefore, MicroPort® is a connected person of the Company under the Listing Rules, and the transactions contemplated under each of the 2026 International Distribution Framework Agreement I and the 2026 International Distribution Framework Agreement II constitute continuing connected transactions for the Company under Chapter 14A of the Listing Rules.

As the highest applicable percentage ratio (other than the profits ratio) in respect of the highest amount of the annual caps under each of the 2026 International Distribution Framework Agreement I and the 2026 International Distribution Framework Agreement II exceeds 0.1% but is less than 5%, the transactions contemplated under each of the 2026 International Distribution Framework Agreement I and the 2026 International Distribution Framework Agreement II are subject to the annual reporting, annual review and announcement requirements but are exempt from circular (including independent financial advice) and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules.

CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE 2026 DISTRIBUTION AGREEMENTS

2026 International Distribution Framework Agreement I

On April 8, 2026 (after trading hours), the Company (for itself and on behalf of its subsidiaries) and MicroPort® (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group) entered into the 2026 International Distribution Framework Agreement I, pursuant to which the Retained MicroPort® Group and its joint ventures and associates agreed to grant the Group a non-exclusive right to distribute certain products, including but not limited to, Cardiovascular Products and EP Products of the Retained MicroPort® Group and its joint ventures and associates in selected overseas regions (including but not limited to Europe) and the Group agreed to procure such products from the Retained MicroPort® Group and its joint ventures and associates and be responsible for their promotion and sale within selected overseas regions (including but not limited to Europe). The principal terms of the 2026 International Distribution Framework Agreement I are set out below:

Date: April 8, 2026

Parties:

- (i) the Company (for itself and on behalf of its subsidiaries); and
- (ii) MicroPort® (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group)

Scope of service: Subject to the terms and conditions set out in the 2026 International Distribution Framework Agreement I, the Retained MicroPort® Group and its joint ventures and associates agreed to grant the Group a non-exclusive right to distribute certain products, including but not limited to, cardiovascular products and EP products manufactured by the Retained MicroPort® Group and its joint ventures and associates (“**MicroPort® Products**”) in selected overseas regions, including but not limited to Europe and the Group agreed to procure such products from the Retained MicroPort® Group and its joint ventures and associates and be responsible for their promotion and sale within selected overseas regions, including but not limited to Europe.

Term: From the date of the 2026 International Distribution Framework Agreement I to December 31, 2028 (both dates inclusive).

Pricing policy:

The purchase price of each of the MicroPort® Products shall be mutually negotiated between parties with reference to the (i) the cost of production, including raw materials, sales, and administrative expenses; (ii) transportation costs; (iii) the prevailing market gross margin for distributing similar products in the respective regions; and (iv) the prevailing market price of similar products in the respective regions, including approved tender prices, where applicable.

The Group will exert reasonable efforts to obtain at least two market quotations from Independent Third Party suppliers (if available) for products comparable to the MicroPort® Products and constantly research into prevailing market conditions and practices and make reference to the pricing and terms between our Group and Independent Third Parties for similar transactions to ensure that the terms for distributing the MicroPort® Products are fair and reasonable, and are determined on normal commercial terms or on terms no less favorable to the Retained MicroPort® Group and its joint ventures and associates than the terms available from Independent Third Parties. Regularly, the Company will review and reassess the sales prices of the MicroPort® Products, making necessary adjustments in response to significant shifts in production costs, market demand, or prevailing market conditions.

Historical transaction amounts:

For each of the years ended December 31, 2024 and 2025 and two months ended February 28, 2026, the historical transaction amount of the distribution of MicroPort® Products by our Group was approximately nil*, nil* and nil*, respectively.

* *On December 19, 2025, the Company completed the Acquisition of MicroPort CRM and MicroPort CRM became a wholly owned subsidiary of the Company since then. Historically, such distribution transactions have historically been carried out on an ongoing basis as part of the customary operations of the MicroPort CRM's business between MicroPort CRM Group and Retained MicroPort® Group (excluding MicroPort CRM Group) and its joint ventures and associates but, following the Acquisition of MicroPort CRM Group, now constitute continuing connected transactions under the Listing Rules.*

For each of the years ended December 31, 2024 and 2025, the distribution of MicroPort® Products by MicroPort CRM Group was approximately US\$3,020,000 and US\$3,133,000, respectively.

Annual caps:

Pursuant to the 2026 International Distribution Framework Agreement I, it is proposed that the annual caps for the transactions contemplated thereunder for the three years ending December 31, 2028 are expected not to exceed as follows:

	For the year ending December 31,		
	2026	2027	2028
	<i>US\$'000</i>	<i>US\$'000</i>	<i>US\$'000</i>
Annual cap	5,000	6,500	7,900

The proposed annual caps for the transactions contemplated under the 2026 International Distribution Framework Agreement I were determined after considering the factors including:

- (i) the historical transaction amounts between MicroPort CRM Group and the Retained MicroPort® Group (excluding MicroPort CRM Group) and its joint ventures and associates which are of the same nature as the transactions contemplated under the 2026 International Distribution Framework Agreement I;
- (ii) the pricing policy of the MicroPort® Products, which is determined through an in-depth evaluation of both cost structures and market conditions to ensure competitiveness and maintain profitability;
- (iii) sales volume projections that are supported by detailed market analyses, historical sales data of the MicroPort® Products overseas, and anticipated market demand increase within Europe;
- (iv) the Retained MicroPort® Group's production capacity, logistical capabilities, and supply chain dynamics, ensuring that operational capacities align with sales expectations; and
- (v) an assessment of the competitive landscape and the Group's sales channels and marketing capabilities.

Payment terms: Payment arrangements will be negotiated by the parties and stated in individual implementation agreements. Subject to compliance with applicable laws and regulations (including but not limited to the Listing Rules) and requirements of securities regulatory authorities, the 2026 International Distribution Framework Agreement I may be renewed for a further term of no longer than three years from time to time. Upon renewal, the parties may amend the terms of such agreement based on the then prevailing circumstances.

2026 International Distribution Framework Agreement II

On April 8, 2026 (after trading hours), the Company (for itself and on behalf of its subsidiaries) and MicroPort® (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group) entered into the 2026 International Distribution Framework Agreement II, pursuant to which the Group agreed to grant the Retained MicroPort® Group and its joint ventures and associates a non-exclusive right to distribute certain CRM Products and LAAC Products manufactured by the Group (the “**Group Products**”) in selected overseas regions markets (including but not limited to emerging markets such as Asia Pacific, Latin America, the Middle East, Africa, and the Commonwealth of the Independent States) and the Retained MicroPort® Group and its joint ventures and associates agreed to procure such products from the Group and handle their promotion and sale in such designated overseas regions. The principal terms of the 2026 International Distribution Framework Agreement II are set out below:

Date: April 8, 2026

Parties: (iii) the Company (for itself and on behalf of its subsidiaries);
and
(iv) MicroPort® (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group)

Scope of service: Subject to the terms and conditions set out in the 2026 International Distribution Framework Agreement II, the Group agreed to grant the Retained MicroPort® Group and its joint ventures and associates a non-exclusive right to distribute certain CRM Products and LAAC Products manufactured by the Group in selected overseas regions markets (including but not limited to emerging markets such as Asia Pacific, Latin America, the Middle East, Africa, and the Commonwealth of the Independent States) and the Retained MicroPort® Group and its joint ventures and associates agreed to procure such products from the Group and handle their promotion and sale in such designated overseas regions.

Term: From the date of the 2026 International Distribution Framework Agreement II to December 31, 2028 (both dates inclusive).

Pricing policy: The purchase price of each of the Group Products shall be mutually negotiated between parties with reference to the (i) the cost of production, including raw materials, sales, and administrative expenses; (ii) transportation costs; (iii) the prevailing market gross margin for distributing similar products in the respective regions; and (iv) the prevailing market price of similar products in the respective regions, including approved tender prices, where applicable. The Finance Department will regularly review and re-assess the sales prices of the Group Products and delivery method semiannually and adjust if there are any significant changes in the production cost, demands or the prevailing market prices. Please refer to the section headed “Internal Control Measures” in this announcement for details.

It is expected that the prices of the Group Products to be charged by the Group to the Retained MicroPort® Group and its joint ventures and associates shall be no less favorable to the Group than prices charged to Independent Third Party distributors, if any, for the same products under similar conditions in the relevant regions, and ensure that the relevant agreements are fair and reasonable, and on normal commercial terms.

Historical transaction amounts: For each of the years ended December 31, 2024 and 2025 and two months ended February 28, 2026, the historical transaction amount of the 2026 International Distribution Framework Agreement II was approximately nil*, US\$17,000* and US\$357,000**, respectively.

* *On December 19, 2025, the Company completed the Acquisition of MicroPort CRM and MicroPort CRM became a wholly owned subsidiary of the Company since then. Historically, the distribution of CRM Products have historically been carried out on an ongoing basis as part of the customary operations of the MicroPort CRM’s business between MicroPort CRM and Retained MicroPort® Group (excluding MicroPort CRM Group) and its joint ventures and associates but, following the Acquisition of MicroPort CRM, now constitute continuing connected transactions under the Listing Rules.*

For each of the years ended December 31, 2024 and 2025, the distribution of CRM Products by the Retained MicroPort® Group was approximately nil and US\$1,579,000, respectively.

** *unaudited management account*

Annual caps:

Pursuant to the 2026 International Distribution Framework Agreement II, it is proposed that the annual caps for the transactions contemplated thereunder for the three years ending December 31, 2028 are expected not to exceed as follows:

	For the year ending December 31,		
	2026	2027	2028
	<i>US\$'000</i>	<i>US\$'000</i>	<i>US\$'000</i>
Annual cap	5,700	7,200	8,600

The proposed annual caps for the transactions contemplated under the 2026 International Distribution Framework Agreement II were determined after considering the factors including:

- (i) the historical transaction amounts in relation to the CRM Products between MicroPort CRM Group and the Retained MicroPort® Group (excluding MicroPort CRM Group) and its joint ventures and associates and the LAAC Products between our Group and the Retained MicroPort® Group and its joint ventures and associates, which are of the same nature as the transactions contemplated under the 2026 International Distribution Framework Agreement II;
- (ii) the pricing policy of the Group Products, which is determined through an in-depth evaluation of both cost structures and market conditions to ensure competitiveness and maintain profitability;
- (iii) sales volume projections that are supported by detailed market analyses, historical overseas sales data of the Group's Products, and anticipated market demand within emerging regions, taking into account that CRM Products only gradually commenced entry into emerging markets such as Latin America, the Middle East and Africa in the second half of 2025. Given the substantial growth potential of these emerging markets and based on the results of the initial market development efforts, sales volume in 2026 is expected to increase significantly compared to 2025, with continued growth anticipated thereafter;
- (iv) the Group's production capacity, logistical capabilities, and supply chain dynamics, ensuring that operational capacities align with sales expectations; and

- (v) an assessment of the competitive landscape and the sales channels and marketing capabilities of the Retained MicroPort® Group and its joint ventures and associates.

Payment terms:

Payment arrangements will be negotiated by the parties and stated in individual implementation agreements. Subject to compliance with applicable laws and regulations (including but not limited to the Listing Rules) and requirements of securities regulatory authorities, the 2026 International Distribution Framework Agreement II may be renewed for a further term of no longer than three years from time to time. Upon renewal, the parties may amend the terms of such agreement based on the then prevailing circumstances.

INTERNAL CONTROL MEASURES

In order to ensure that the transactions contemplated under 2026 Distribution Agreements will be conducted on normal commercial terms or better, the Group has adopted the following measures:

- (1) the Company places great importance on the management of connected transactions and takes the initiative to actively update the list of connected persons. In order to identify connected persons comprehensively and accurately, the Company conducts penetration management of substantial Shareholders to achieve effective collection of data related to connected transactions. To meet the management requirements of the Stock Exchange in relation to connected transactions, the Company has formulated internal guidelines for connected transactions based on the applicable requirements under the Listing Rules, which further clarifies the duties of each functional department with respect to the connected transactions so as to ensure that all the connected transactions of the Company are effectively monitored and supervised and all relevant connected transactions are in the interests of the Company and the Shareholders as a whole;
- (2) the internal audit department of the Group will supervise and monitor the individual agreements to be entered into between the Group and the Retained MicroPort® Group and its joint ventures and associates to ensure that they will be entered into in accordance with the pricing policy under 2026 Distribution Agreements;
- (3) the Finance Department will constantly research into prevailing market conditions and practices and make reference to the pricing and terms between the Group and Independent Third Parties for similar transactions, and review and compare at least two quotations from Independent Third Parties, if available, with the quotes from the Retained MicroPort® Group and its joint ventures and associates when determining which supplier to engage with so as to ensure that the price provided by the Retained MicroPort® Group and its joint ventures and associates to the Group is fair and

reasonable, and is determined on normal commercial terms or on terms no less favorable to the Group than the terms available from Independent Third Parties, if applicable;

- (4) the Finance Department will further negotiate with the Retained MicroPort® Group and its joint ventures and associates in respect of the quotations if (i) there is any material difference between the quotations provided by the Retained MicroPort® Group and its joint ventures and associates and the historical comparable transactions of similar nature provided by the Retained MicroPort® Group and its joint ventures and associates; and/or (ii) the quotations provided by the Retained MicroPort® Group and its joint ventures and associates are higher than the overall cost (mainly the labor cost) the Group may incur for conducting similar activities by the Group's in-house sales and marketing personnel or the similar products/services previously purchased or supplied by the Group;
- (5) the Group will comply with the annual review requirements in respect of the transactions contemplated under the 2026 Distribution Agreements in accordance with Chapter 14A of the Listing Rules, such as engaging the Company's auditor to conduct annual review and having the independent non-executive Directors to review the transactions contemplated under such agreements and give opinions/confirmations in the Company's annual reports;
- (6) the Board and Securities Affairs Department will arrange internal trainings for the senior management of the Group and responsible staff on the compliance requirements for continuing connected transactions;
- (7) the Finance Department will monitor the transaction amounts under the 2026 Distribution Agreements by preparing designated management accounts for the continuing connected transactions therein on a monthly basis to make sure that the actual contract amounts do not exceed the relevant annual caps, if applicable. If it is expected that the transaction amount of any continuing connected transaction that is or will be incurred in the financial year will reach or exceed the relevant annual caps, the Finance Department shall report to the management and consider the measures to be taken to ensure that the requirements under the Listing Rules are complied with, including obtaining the approval of independent Shareholders (if required);
- (8) the Group shall comply with the conditions prescribed under the waiver granted by the Stock Exchange in connection with the connected transactions under the 2026 Distribution Agreements; and
- (9) if any revision or adjustment on the terms (including without limitation, the price of the services or products) of the individual agreement under the 2026 Distribution Agreements is necessary, provided such revision or adjustment is in compliance with the 2026 Distribution Agreements, an approval application will be made by the total solutions promotion department of the Group and approved by, among others, the board secretary office of the Group.

REASONS FOR AND BENEFITS OF THE TRANSACTIONS UNDER THE 2026 DISTRIBUTION AGREEMENTS

The transactions contemplated under the 2026 Distribution Agreements are primarily conducted between the MicroPort CRM Group and the Retained MicroPort® Group and predominantly arise from the business of MicroPort CRM newly acquired by the Group. These transactions have historically been carried out on an ongoing basis as part of the customary operations of the business of MicroPort CRM but, following the Acquisition of MicroPort CRM, now constitute continuing connected transactions under the Listing Rules. The 2026 Distribution Agreements are designed to formalize and regulate these established business arrangements, ensuring compliance with applicable requirements under the Listing Rules while maintaining the continuity of the MicroPort CRM-related transactions.

The Retained MicroPort® Group has a proven track record of commercializing medical devices globally, supported by its experienced global sales and marketing team familiar with the Group's TAVI products. Since January 2024, the Group has engaged the Retained MicroPort® Group as the overseas distributor of its TAVI products, leveraging the Retained MicroPort® Group's expertise in global markets. Additionally, the Retained MicroPort® Group's strengths in distributing medical products in emerging markets, such as Asia Pacific, Latin America, the Middle East, Africa, and the Commonwealth of the Independent States make it well-positioned to distribute the Group's CRM products and LAAC products.

Conversely, the Group, through the MicroPort CRM, has developed robust sales channels and extensive experience in distributing cardiology products in Europe. The MicroPort CRM Group has been the distributor of MicroPort® Products, forming part of the Group's transactions. These complementary capabilities allow both parties to leverage their respective strengths and established networks effectively.

The 2026 Distribution Agreements will allow the Group to continue benefiting from the Retained MicroPort® Group's well-established global distribution network and expertise in international markets to drive incremental revenue growth and expand the market penetration of its products. At the same time, the 2026 Distribution Agreements will enable the Group to leverage its marketing and distribution capabilities in Europe to promote and sell the high-end medical devices of the Retained MicroPort® Group that have high synergies with the Group's structural heart disease products and CRM products in terms of channels, hospitals, and clinical departments in European markets, further strengthening its product portfolio while supporting the Retained MicroPort® Group's global expansion efforts.

The 2026 Distribution Agreements are mutually beneficial and are expected to enhance the operational efficiency, market presence, and revenue generation of both parties while ensuring compliance with applicable regulatory requirements.

INFORMATION OF THE PARTIES

The Company is incorporated in the Cayman Islands with limited liability. The Company is a global leader in innovation within the field of structural heart intervention and CRM dedicated to providing physicians and patients with innovative, full-cycle heart failure health management services and building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.

MicroPort® is incorporated in the Cayman Islands and the shares of which are listed on the Main Board of the Stock Exchange (stock code: 00853). MicroPort® Group is a leading medical device group focusing on innovating, manufacturing and marketing high-end medical devices globally in a broad range of business segments including cardiovascular, orthopedics, endovascular, comprehensive heart failure management, surgical robot and other business.

LISTING RULES IMPLICATIONS

As at the date of this announcement, MicroPort®, through its wholly-owned subsidiaries Shanghai MicroPort Limited and MicroPort International Corp. Limited, was indirectly interested in approximately 44.45% of the total issued share capital of the Company. Therefore, MicroPort® is a connected person of the Company under the Listing Rules, and the transactions contemplated under each of the 2026 International Distribution Framework Agreement I and the 2026 International Distribution Framework Agreement II constitute continuing connected transactions for the Company under Chapter 14A of the Listing Rules.

As the highest applicable percentage ratio (other than the profits ratio) in respect of the highest amount of the annual caps under each of the 2026 International Distribution Framework Agreement I and the 2026 International Distribution Framework Agreement II exceeds 0.1% but is less than 5%, the transactions contemplated under each of the 2026 International Distribution Framework Agreement I and the 2026 International Distribution Framework Agreement II are subject to the annual reporting, annual review and announcement requirements but are exempt from circular (including independent financial advice) and independent Shareholders' approval requirements under Chapter 14A of the Listing Rules.

BOARD APPROVAL

Taking into account the factors mentioned above, the Directors (including the independent non-executive Directors) consider that the 2026 Distribution Agreements were determined arm's length negotiation, the terms and the proposed annual caps thereunder are fair and reasonable and the transactions contemplated thereunder are on normal commercial terms and in the ordinary and usual course of business of the Company, and in the interests of the Company and the Shareholders as a whole.

As at the date of this announcement, each of Mr. Chen Guoming, Dr. Brian Chang, Ms. Wu Xia and Mr. Jonathan H. Chou, who are Directors appointed by MicroPort®, a connected person of MicroPort®, or currently hold directorships in the MicroPort® Group, has abstained from approving the relevant Board resolutions of the Company in relation to the 2026 Distribution Agreements. Save as disclosed above, to the best knowledge, belief and information of the Company and having made all reasonable enquiries, none of the Directors has any material interest or is required to abstain from voting on the relative Board resolution approving the same.

DEFINITIONS

In this announcement, the following expressions shall have the meaning set out below unless the context requires otherwise:

“2026 Distribution Agreements”	2026 International Distribution Framework Agreement I and 2026 International Distribution Framework Agreement II
“2026 International Distribution Framework Agreement I”	the 2026 international distribution framework agreement I entered into between the Company (for itself and on behalf of its subsidiaries) and MicroPort® (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group) on April 8, 2026, pursuant to which the Retained MicroPort® Group and its joint ventures and associates agreed to grant the Group a non-exclusive right to distribute certain products, including but not limited to, Cardiovascular Products and EP Products of the Retained MicroPort® Group and its joint ventures and associates in selected overseas regions (including but not limited to Europe) and the Group agreed to procure such products from the Retained MicroPort® Group and its joint ventures and associates and be responsible for their promotion and sale within selected overseas regions (including but not limited to Europe)

“2026 International Distribution Framework Agreement II”	the 2026 international distribution framework agreement II entered into between the Company (for itself and on behalf of its subsidiaries) and MicroPort® (for itself and on behalf of its subsidiaries and its joint ventures and associates other than the Group) on April 8, 2026, pursuant to which the Group agreed to grant the Retained MicroPort® Group and its joint ventures and associates a non-exclusive right to distribute certain CRM Products and LAAC Products manufactured by the Group (the “ Group Products ”) in selected overseas regions markets (including but not limited to emerging markets such as Asia Pacific, Latin America, the Middle East, Africa, and the Commonwealth of the Independent States) and the Retained MicroPort® Group and its joint ventures and associates agreed to procure such products from the Group and handle their promotion and sale in such designated overseas regions
“Acquisition of MicroPort CRM”	the acquisition of the 100% equity interest of MicroPort CRM by the Company by way of merger, which was completed on December 19, 2025
“Board”	the board of Directors
“Cardiovascular Products”	cardiovascular products manufactured by the Retained MicroPort® Group and its joint ventures and associates such as Firefighter™ NC Balloon Catheter and Firehawk Liberty™ and other products
“Company”	MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司), an exempted company incorporated in the Cayman Islands with limited liability, whose shares are listed on the Main Board of the Stock Exchange (stock code: 2160)
“connected person”	has the meaning ascribed thereto under the Listing Rules
“connected transaction”	has the meaning ascribed to it under the Listing Rules
“CRM”	cardiac rhythm management
“CRM Products”	products in relation to CRM manufactured by MicroPort CRM Group, such as pacemaker and lead and other products
“Directors”	the directors of the Company

“EP Products”	electrophysiology products manufactured by the Retained MicroPort® Group and its joint ventures and associates such as IceMagic® CryoAblation Console and FireMagic® TrueForce® Ablation Catheter and other products
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Independent Third Party(ies)”	a person, or in the case of a company, the company or its ultimate beneficial owner(s), who is independent of and not connected with the Group and its connected persons and their respective ultimate beneficial owner(s) or their respective associates
“LAAC Products”	left atrial appendage closure products manufactured by the Group, such as AnchorMan® LAAC System and AnchorMan® LAAC Access System
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Stock Exchange. For the avoidance of doubt, the Main Board excludes the Growth Enterprise Market of the Stock Exchange
“MicroPort®”	MicroPort Scientific Corporation (微創醫療科學有限公司), an exempted company incorporated in the Cayman Islands with limited liability whose shares are listed on the Main Board of the Stock Exchange (stock code: 00853)
“MicroPort® Group”	MicroPort®, its subsidiaries, associates and joint ventures
“MicroPort CRM”	MicroPort Cardiac Rhythm Management Limited (微創心律管理有限公司), a company incorporated under the laws of the Cayman Islands with limited liability and a wholly-owned subsidiary of our Company
“MicroPort CRM Group”	MicroPort CRM and its subsidiaries

“PRC”	the People’s Republic of China, for the purpose of this announcement, shall not include Hong Kong, Macau Special Administrative Region and Taiwan
“Retained MicroPort® Group”	MicroPort® and its subsidiaries, excluding the Group
“Shareholder(s)”	the registered holder(s) of the share(s) of the Company
“Stock Exchange”	the Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed thereto under the Listing Rules
“TAVI”	transcatheter aortic heart valve implantation, a catheter-based technique to implant a new aortic valve in a minimally invasive procedure that does not involve open-chest surgery to correct severe aortic stenosis
“US\$”	United States dollars, the lawful currency of the United States
“%”	per cent

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, April 8, 2026

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.